The principal efficacy endpoint was improve from baseline MADRS score. This small-expression analyze observed that, compared to intranasal placebo furthermore oral antidepressant, intranasal esketamine in conjunction with an oral antidepressant significantly enhanced depressive signs or symptoms after 4 months by a necessarily mean difference of 4 points on the MADRS. https://paulc157ybk8.elbloglibre.com/profile